The Autism Spectrum Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Autism Spectrum Disorder: An Overview
Autism spectrum disorder (ASD) refers to a neurodevelopmental disorder that is characterized by difficulties with social communication and social interaction and restricted and repetitive patterns in behaviors, interests, and activities. By definition, the symptoms are present early on in development and affect daily functioning. The term ‘spectrum’ is used because of the heterogeneity in the presentation and severity of Autism Spectrum Disorder (ASD) symptoms, as well as in the skills and level of functioning of individuals who have Autism Spectrum Disorder (ASD).
The current treatment options for the core symptoms of autism are limited to psychosocial therapies, such as applied behavior analysis. Applied behavior analysis is a treatment based on theories of learning and operant conditioning. It includes specific intervention targets, coupled with positive reinforcement (verbal praise, tokens, or edible rewards), with repetition of learning trials a key component.
Autism Spectrum Disorder Market Key Facts
-
According to British Medical Association, it is estimated that there are around 700,000 people in the UK, including one in 100 children, with a diagnosis of autism spectrum disorder.
-
According to the US Centers for Disease Control and Prevention (CDC) approximately, 1 in 68 children in the United States have been diagnosed with Autism. Autism is the third most common developmental disability.
-
As per the study by Dietz et al. (2020), in the U.S., approximately 1.5 million children ages 3–17 years have been diagnosed with Autism Spectrum Disorder (ASD).
Autism Spectrum Disorder Market
Autism Spectrum Disorder (ASD) market size is expected to increase during the forecast period owing to the increasing prevalent population and growing awareness among the people through programs and initiatives.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Autism Spectrum Disorder market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Autism Spectrum Disorder market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Autism Spectrum Disorder Epidemiology
The epidemiology section covers insights about the historical and current Autism Spectrum Disorder patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Autism Spectrum Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autism Spectrum Disorder market or expected to get launched in the market during the study period. The analysis covers Autism Spectrum Disorder market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Autism Spectrum Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Autism Spectrum Disorder Therapeutics Analysis
Currently, no treatment has been shown to cure Autism Spectrum Disorder (ASD), but several interventions have been developed and studied for use with young children. These interventions may reduce symptoms, improve cognitive ability and daily living skills, and maximize the ability of the child to function and participate in the community.
The dynamics of the Autism Spectrum Disorders market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
Autism Spectrum Disorder Treatment Algorithm
Medications have been most effective in treating the associated behavioral symptoms of autism, though studies have examined potential benefits in some of the core symptoms of autism with certain medications, especially the repetitive behaviors often seen with the diagnosis.
Risperidone and Aripiprazole are currently the only medications FDA approved for symptoms associated with autism spectrum disorders, targeting the irritability often seen with this diagnosis. Besides, Slenyto is the first and only pharmacotherapy that is approved for the treatment of insomnia in children with Autism Spectrum Disorder (ASD).
Intravenous immunoglobulin therapy has been suggested as a potential treatment for autism spectrum disorder. However, there are no randomized controlled trials examining this treatment in children and adolescents with autism.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-market
Some of the key companies in the Autism Spectrum Disorder (ASD) Market include:
-
Curemark
-
Otsuka Pharmaceutical
-
Janssen Pharmaceutical
-
GW Research
-
Roche
-
Finch Therapeutics
And many others.
Autism Spectrum Disorder (ASD) therapies covered in the report include:
-
CM-AT
-
Brexpiprazole
-
JNJ-42165279
-
GWP42006
-
RO 7017773
-
CP101
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-market
Table of Content
1. Key Insights
2. Executive Summary
3. Autism Spectrum Disorder Competitive Intelligence Analysis
4. Autism Spectrum Disorder Market Overview at a Glance
5. Autism Spectrum Disorder Disease Background and Overview
6. Autism Spectrum Disorder Patient Journey
7. Autism Spectrum Disorder Epidemiology and Patient Population
8. Autism Spectrum Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Autism Spectrum Disorder Unmet Needs
10. Key Endpoints of Autism Spectrum Disorder Treatment
11. Autism Spectrum Disorder Marketed Products
12. Autism Spectrum Disorder Emerging Therapies
13. Autism Spectrum Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Autism Spectrum Disorder Market Outlook (7 major markets)
16. Autism Spectrum Disorder Access and Reimbursement Overview
17. KOL Views on the Autism Spectrum Disorder Market.
18. Autism Spectrum Disorder Market Drivers
19. Autism Spectrum Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/autism-spectrum-disorder-asd-market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/